Who is sponsoring NCT00723632?

NCT00723632 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT00723632 study?

NCT00723632 studies Hepatitis C, Chronic, Hepatitis C.

What drugs are being tested in NCT00723632?

Interventions: peginterferon alfa-2b, ribavirin.

What is the status of NCT00723632?

NCT00723632 is currently COMPLETED.

Last reviewed 2015-10-01 · How we verify

Cost of Treatment of Chronic Hepatitis C Using Combination of Peginterferon α-2b Plus Ribavirin

NCT00723632 COMPLETED Results posted

The objective of the study is to evaluate the costs associated with peginterferon alfa-2b (PegIntron) plus ribavirin (Rebetol) treatment for chronic hepatitis C in the Czech Republic. Only costs associated with rescue medication, concomitant therapy, disease monitoring, and medical intervention costs recognized by the treating institution as treatment-related expenses will be included in the analysis. The study will also evaluate the correlation between hepatitis C virus (HCV) therapy-related costs with ribavirin dosing and participant history.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Status	COMPLETED
Enrolment	901
Start date	2005-09
Completion	2010-12

Conditions

Hepatitis C, Chronic
Hepatitis C

Interventions

peginterferon alfa-2b
ribavirin

Primary outcomes

Average Cost Per Participant With Sustained Virologic Response (SVR) Stratified by Weight Category — From enrollment up to 48 weeks for participants with hepatitis C virus (HCV) genotype 1, and from enrollment up to 24 weeks for participants with HCV genotypes 2 and 3
SVR is defined as undetectable HCV ribonucleic acid (RNA) six months after the end of treatment. Cost per participant with SVR was calculated as a ratio of the total costs for all participants and the number of participants with SVR in the given group. All costs were adjusted for inflation to 2010 values.